• Anticonvulsant Shows Promise in Major Depression

    14 days ago - By Medscape

    Ezogabine, a potassium channel opener that reduces depressive symptoms and increases resilience to stress, may provide a new molecular target for mood research.
    Medscape Medical News
    Read more ...

     

  • Ezogabine may decrease symptoms in major depression

    14 days ago - By Healio

    Patients with major depressive disorder experienced reduced depressive symptoms after receiving treatment with the FDA-approved anticonvulsant ezogabine, according to study data.
    “Recent preclinical evidence has highlighted the KCNQ-type voltage-gated potassium channel as a promising novel molecular target for the treatment of depression,” Aaron Tan, PhD candidate, from the departments of psychiatry and neuroscience, Icahn School of Medicine at Mount Sinai, and colleagues wrote in Molecular Psychiatry. “Systemic injection of ezogabine, a KCNQ-selective potassium channel
    Read more ...